<DOC>
	<DOC>NCT00141102</DOC>
	<brief_summary>To determine whether celecoxib is superior to combined therapy with diclofenac and omeprazole in the incidence of clinically significant upper and/or lower gastrointestinal (GI) events in high GI risk subjects with osteoarthritis and/or rheumatoid arthritis.</brief_summary>
	<brief_title>Study Of Celecoxib Or Diclofenac And Omeprazole For Gastrointestinal (GI) Safety In High GI Risk Patients With Arthritis</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Arthritis, Rheumatoid</mesh_term>
	<mesh_term>Omeprazole</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Subjects with a clinical diagnosis of OA or RA and who are expected to require regular antiinflammatory therapy for arthritis symptom management Subjects must be aged 60 years or older with or without a history of gastroduodenal (GD) ulceration; or be of any age 18 years or older and have had documented evidence of GD ulceration 90 days or more prior to the screening visit Active GD ulceration or GD ulceration within 90 days of the screening visit. Concomitant use of low dose aspirin Previous MI, stroke or significant vascular disease.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2011</verification_date>
	<keyword>GI events in high risk GI arthritis patients</keyword>
</DOC>